Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis: Disease-Modifying Antirheumatic Drugs
The American Journal of the Medical Sciences, 05/09/2012
Soriano SR et al. – Surprisingly, little data are available for the use of disease–modifying antirheumatic drugs in ankylosing spondylitis. Sulfasalazine has been the best studied. Efficacy data for individual agents (including pamidronate) and combinations of agents are detailed in this review. Intriguingly, these agents continue to be used with some frequency, even in the absence of efficacy data. To answer these questions, additional systematic studies of these agents in ankylosing spondylitis are needed and will likely need to be done by interested collaborative groups such as SPARTAN.